Case report: Inability to achieve a therapeutic dose of tacrolimus in a pediatric allogeneic stem cell transplant patient after generic substitution

Ashraf G. Madian, Arun R Panigrahi, Minoli A. Perera, Navin Pinto

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Tacrolimus is an immunosuppressive drug that is used to lower the activity of the patient's immune system to prevent organ rejection. Unfortunately, there is limited data regarding the therapeutic equivalency of generic tacrolimus formulations especially in children. We report the case of a pediatric patient having an inability to achieve a therapeutic trough level for tacrolimus after conversion from brand name to the generic formulation. Case presentation: A 17-month-old male patient diagnosed with T-cell acute lymphoblastic leukemia underwent allogeneic stem cell transplantation. The patient initially received intravenous (IV) tacrolimus for graft-versus-host disease (GVHD) prophylaxis and achieved therapeutic levels. The patient was then switched to an oral brand formulation of tacrolimus, and was able to maintain trough levels within the therapeutic range. After being discharged, the patient received the generic formulation of tacrolimus from an outside pharmacy and the care team was unable to reach therapeutic levels despite multiple dose escalations. Returning to brand name tacrolimus resulted in prompt achievement of therapeutic levels. Conclusions: A likely etiology for the inability to achieve therapeutic trough levels in this patient is the change in formulation from brand formulation to generic version. Other factors including drug-drug interaction, preparation of the medication by a different pharmacy, drug-food interaction and genetic factors were also considered. Physicians and pharmacists must be aware of the inability to achieve targeted therapeutic concentrations of tacrolimus resulting from the conversion of brand name to the generic formulation until these generic formulations are tested in clinical trials in a pediatric population.

Original languageEnglish (US)
Article number69
JournalBMC Pharmacology and Toxicology
Volume15
Issue number1
DOIs
StatePublished - Dec 3 2014
Externally publishedYes

Fingerprint

Drug Substitution
Tacrolimus
Stem Cells
Pediatrics
Transplants
Names
Therapeutics
Food-Drug Interactions
A 17
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Therapeutic Equivalency
Drug Compounding
Stem Cell Transplantation
Graft vs Host Disease
Immunosuppressive Agents
Drug Interactions
Pharmacists
Pharmaceutical Preparations
Immune System
Clinical Trials

Keywords

  • Children
  • Generic
  • Tacrolimus

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Medicine(all)

Cite this

Case report : Inability to achieve a therapeutic dose of tacrolimus in a pediatric allogeneic stem cell transplant patient after generic substitution. / Madian, Ashraf G.; Panigrahi, Arun R; Perera, Minoli A.; Pinto, Navin.

In: BMC Pharmacology and Toxicology, Vol. 15, No. 1, 69, 03.12.2014.

Research output: Contribution to journalArticle

@article{d88fb3e55574425f8cd3bc40391c4f98,
title = "Case report: Inability to achieve a therapeutic dose of tacrolimus in a pediatric allogeneic stem cell transplant patient after generic substitution",
abstract = "Background: Tacrolimus is an immunosuppressive drug that is used to lower the activity of the patient's immune system to prevent organ rejection. Unfortunately, there is limited data regarding the therapeutic equivalency of generic tacrolimus formulations especially in children. We report the case of a pediatric patient having an inability to achieve a therapeutic trough level for tacrolimus after conversion from brand name to the generic formulation. Case presentation: A 17-month-old male patient diagnosed with T-cell acute lymphoblastic leukemia underwent allogeneic stem cell transplantation. The patient initially received intravenous (IV) tacrolimus for graft-versus-host disease (GVHD) prophylaxis and achieved therapeutic levels. The patient was then switched to an oral brand formulation of tacrolimus, and was able to maintain trough levels within the therapeutic range. After being discharged, the patient received the generic formulation of tacrolimus from an outside pharmacy and the care team was unable to reach therapeutic levels despite multiple dose escalations. Returning to brand name tacrolimus resulted in prompt achievement of therapeutic levels. Conclusions: A likely etiology for the inability to achieve therapeutic trough levels in this patient is the change in formulation from brand formulation to generic version. Other factors including drug-drug interaction, preparation of the medication by a different pharmacy, drug-food interaction and genetic factors were also considered. Physicians and pharmacists must be aware of the inability to achieve targeted therapeutic concentrations of tacrolimus resulting from the conversion of brand name to the generic formulation until these generic formulations are tested in clinical trials in a pediatric population.",
keywords = "Children, Generic, Tacrolimus",
author = "Madian, {Ashraf G.} and Panigrahi, {Arun R} and Perera, {Minoli A.} and Navin Pinto",
year = "2014",
month = "12",
day = "3",
doi = "10.1186/2050-6511-15-69",
language = "English (US)",
volume = "15",
journal = "BMC pharmacology & toxicology",
issn = "2050-6511",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Case report

T2 - Inability to achieve a therapeutic dose of tacrolimus in a pediatric allogeneic stem cell transplant patient after generic substitution

AU - Madian, Ashraf G.

AU - Panigrahi, Arun R

AU - Perera, Minoli A.

AU - Pinto, Navin

PY - 2014/12/3

Y1 - 2014/12/3

N2 - Background: Tacrolimus is an immunosuppressive drug that is used to lower the activity of the patient's immune system to prevent organ rejection. Unfortunately, there is limited data regarding the therapeutic equivalency of generic tacrolimus formulations especially in children. We report the case of a pediatric patient having an inability to achieve a therapeutic trough level for tacrolimus after conversion from brand name to the generic formulation. Case presentation: A 17-month-old male patient diagnosed with T-cell acute lymphoblastic leukemia underwent allogeneic stem cell transplantation. The patient initially received intravenous (IV) tacrolimus for graft-versus-host disease (GVHD) prophylaxis and achieved therapeutic levels. The patient was then switched to an oral brand formulation of tacrolimus, and was able to maintain trough levels within the therapeutic range. After being discharged, the patient received the generic formulation of tacrolimus from an outside pharmacy and the care team was unable to reach therapeutic levels despite multiple dose escalations. Returning to brand name tacrolimus resulted in prompt achievement of therapeutic levels. Conclusions: A likely etiology for the inability to achieve therapeutic trough levels in this patient is the change in formulation from brand formulation to generic version. Other factors including drug-drug interaction, preparation of the medication by a different pharmacy, drug-food interaction and genetic factors were also considered. Physicians and pharmacists must be aware of the inability to achieve targeted therapeutic concentrations of tacrolimus resulting from the conversion of brand name to the generic formulation until these generic formulations are tested in clinical trials in a pediatric population.

AB - Background: Tacrolimus is an immunosuppressive drug that is used to lower the activity of the patient's immune system to prevent organ rejection. Unfortunately, there is limited data regarding the therapeutic equivalency of generic tacrolimus formulations especially in children. We report the case of a pediatric patient having an inability to achieve a therapeutic trough level for tacrolimus after conversion from brand name to the generic formulation. Case presentation: A 17-month-old male patient diagnosed with T-cell acute lymphoblastic leukemia underwent allogeneic stem cell transplantation. The patient initially received intravenous (IV) tacrolimus for graft-versus-host disease (GVHD) prophylaxis and achieved therapeutic levels. The patient was then switched to an oral brand formulation of tacrolimus, and was able to maintain trough levels within the therapeutic range. After being discharged, the patient received the generic formulation of tacrolimus from an outside pharmacy and the care team was unable to reach therapeutic levels despite multiple dose escalations. Returning to brand name tacrolimus resulted in prompt achievement of therapeutic levels. Conclusions: A likely etiology for the inability to achieve therapeutic trough levels in this patient is the change in formulation from brand formulation to generic version. Other factors including drug-drug interaction, preparation of the medication by a different pharmacy, drug-food interaction and genetic factors were also considered. Physicians and pharmacists must be aware of the inability to achieve targeted therapeutic concentrations of tacrolimus resulting from the conversion of brand name to the generic formulation until these generic formulations are tested in clinical trials in a pediatric population.

KW - Children

KW - Generic

KW - Tacrolimus

UR - http://www.scopus.com/inward/record.url?scp=84924411523&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924411523&partnerID=8YFLogxK

U2 - 10.1186/2050-6511-15-69

DO - 10.1186/2050-6511-15-69

M3 - Article

C2 - 25472557

AN - SCOPUS:84924411523

VL - 15

JO - BMC pharmacology & toxicology

JF - BMC pharmacology & toxicology

SN - 2050-6511

IS - 1

M1 - 69

ER -